Major Bioactive Prenylated Flavonoids from Humulus lupulus L., Their Applications in Human Diseases and Structure-Activity Relationships (SAR) - A Review
View/ Open
Access
info:eu-repo/semantics/openAccessAttribution-NonCommercial 3.0 United Stateshttp://creativecommons.org/licenses/by-nc/3.0/us/Date
2024Author
Cömert Önder, FerahKalın, Sevil
Şahin, Nebahat
Davutlar, Gülce
Abusharkh, Khaled A.N.
Maraba, Özlem
Ay, Mehmet
Hal, Rabia Selina
Metadata
Show full item recordCitation
Önder, F. C., Kalın, S., Şahin, N., Davutlar, G., Abusharkh, K. A. N., Maraba, O., … Sarker, S. D. (2024). Major Bioactive Prenylated Flavonoids from Humulus lupulus L., Their Applications in Human Diseases and Structure-Activity Relationships (SAR) – A Review. Pharmaceutical Sciences, 30(1), 1–20. https://doi.org/10.34172/PS.2023.18Abstract
In recent years, the incidence of cancers, inflammatory diseases, Alzheimer's disease, glucose metabolism disorder and diabetes has increased alarmingly which demands more research into the discovery of new drug candidates to treat these human diseases. Main phytochemicals from Humulus lupulus L. (hops) have been demonstrated to have positive impacts on human health, and prenylated flavonoids are one of the major groups of bioactive phytochemicals found in this plant. Thus, this review summarizes the role of major prenylated components in hops in human diseases including cancer, inflammation and viral infections. In silico studies of prenylated bioactive compounds against various drug targets such as histone deactylases (HDACs), sirtuins (SIRTs), and acetylcholinesterase (AChE), and the molecular molecular interactions between protein and ligand have also been included. Furthermore, the structure-activity relationships (SAR) studies on these compounds are highlighted. This review concludes that the prenylated phytochemicals from H. lupulus L., including xanthohumol (XN), isoxanthohumol (IXN), 8-prenylnaringenin (8-PN) and 6-prenylnaringenin (6-PN), have promising roles in human health and may contribute to new drug discovery and development.
Volume
30Issue
1The following license files are associated with this item: